Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization

This study employs a dual-cohort design to develop and validate a prognostic model for Major Adverse Cardiovascular Events (MACE) following revascularization in immune thrombocytopenia (ITP) patients with Coronary Artery Disease (CAD). The model will be developed and trained using a retrospective multi-center cohort (development/training cohort). Its performance will then be prospectively validated in a separate, consecutively enrolled prospective cohort (validation cohort). The goal is to create an AI-based tool to assist in personalized risk assessment and decision-making for this high-risk population.

NCT Number	NCT07426107
Lead Sponsor	Xiao Hui Zhang Collaborators: Chinese Academy of Medical Sciences, Fuwai Hospital, Beijing Anzhen Hospital, Peking University Third Hospital, Chinese PLA General Hospital, Peking Union Medical College
Conditions	Immune Thrombocytopenic Purpura, Coronary Artery Disease
Enrollment	600 participants
Start Date	2026-02-25
Primary Completion	2028-02-25 (estimated)
Study Completion	2029-02-25 (estimated)
Updated on ClinicalTrials.gov	2026-02-23